# The Target ALS Global Natural History Study: Cross-platform proteomics to accelerate biofluid biomarker and drug target discovery in amyotrophic lateral sclerosis.

- **DOI:** [10.64898/2026.06.13.26355379](https://doi.org/10.64898/2026.06.13.26355379)
- **Rating:** Sound (3.0 out of 5)
- **Verdict:** Matched-platform ALS proteomics yields a useful discovery resource, but unadjusted case-control analyses limit confidence in disease-specific biomarker claims.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-10-08
- **Evaluation page:** https://www.nabu.science/paper/10.64898%2F2026.06.13.26355379

## Key claims

1. We identified 2,875 proteins in CSF and 1,118 proteins in plasma and identified known and novel differentially expressed proteins (DEPs) between controls and sALS, some of which were orthogonally validated using immunoassay.
   - Support: Supported
   - Type: Primary finding
   - Basis: cross-sectional discovery with modest cohorts and validation limited to three selected proteins
   - Location: Abstract
2. Comparison of TMTpro-MS and Olink proximity extension assay proteomics revealed common and non-overlapping differentially expressed proteins illustrating strengths unique to each platform.
   - Support: Tentative
   - Type: Secondary
   - Basis: different protein libraries and sample subsets limit inference from differential-expression overlap
   - Location: Abstract
3. A total of 149 proteins were increased and 148 proteins decreased in sALS compared with healthy controls.
   - Support: Supported
   - Type: Secondary
   - Basis: directly reported FDR-controlled comparison without covariate adjustment
   - Location: Results, “Proteomic analysis of differentially expressed proteins in sALS CSF”

## Strengths

- **Matched cross-platform biofluid profiling** TMTpro-MS and Olink were compared on overlapping CSF and plasma samples, allowing direct description of common and non-overlapping detected proteins and DEPs.
  - Dimension: contribution
  - Location: Results, “Comparison of 35plex TMTpro-MS to antibody-based proteomics”
- **Detailed contemporary proteomic workflow** The Methods specify immunodepletion, 35-plex labelling, high-pH fractionation, FAIMS-enabled Orbitrap acquisition, Percolator FDR control, pooled-reference normalisation, and BH correction.
  - Dimension: methodological rigour
  - Location: Methods, protein preparation through “Statistical analysis”
- **Independent validation reports mixed results** ELISA testing in a separate cohort reproduced increased CKM and SERPINA3 while openly reporting that CHAD did not replicate.
  - Dimension: methodological rigour
  - Location: Results, “ELISA validation of 35plex TMTpro-MS hits,” Figure 5

## Limitations

- **Disease comparisons lack covariate adjustment** The primary sALS-versus-control analyses use Welch tests without adjustment for available age, sex, site, or clinical variables, limiting disease-specific interpretation of the DEPs.
  - Dimension: methodological rigour
  - Location: Methods, “TALS GNHS Cohort” and “Statistical analysis”
- **Sensitivity claims exceed comparative design** DEP totals from different protein libraries and unequal sample subsets are treated as evidence of superior platform sensitivity without a common reference standard.
  - Dimension: reporting
  - Location: Results, cross-platform and tissue-enrichment sections; Conclusions, paragraphs 5–6
- **Validation and generalisation remain limited** Only three proteins underwent independent ELISA testing, one did not replicate, and no site-, demographic-, or disease-stage-stratified analyses are reported.
  - Dimension: application pathway
  - Location: Methods, “Validation Cohort”; Results, “ELISA validation,” Figure 5

## Reliability checks

Caveats (4 of 4 checks).

- **Results check:** Clean. The reported numbers and statistics are consistent with the stated results.
- **Reporting and transparency:** Noted. Protein-count definitions are not reconciled between the initial analyses and cross-platform comparisons, and the unrestricted-access description requires qualification because portal approval is required.
  - Conflict of interest: not stated · Ethics approval: declared · Preregistration: declared · Data availability: declared
- **Reference integrity:** Clean
  - 45 references in manuscript
  - 45 of 45 checkable references found in an index
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
